BACKGROUND: One-way endobronchial valve (EBV) treatment has shown safety and efficacy at 6 months after treatment in patients with severe emphysema and confirmed absence of interlobar collateral ventilation. Longer follow-up in this subgroup is not available. OBJECTIVES: To investigate the efficacy and safety of EBV treatment of the STELVIO cohort at a 1-year follow-up. METHODS: Emphysema patients who have been treated with EBV in the STELVIO trial were invited for a voluntary 1-year follow-up visit. Both the original treatment group and the control group who crossed over to treatment have been included. Analyses are performed on the patients who attended the 1-year follow-up visit. RESULTS: Sixty-four patients received EBV treatment. At 1 year, 40 patients (26 female; mean age 59 ± 8 years; FEV1 0.86 ± 0.29 L; RV 4.56 ± 1.00 L; 6MWD 367 ± 78 m; and SGRQ 56 ± 13 points) visited the hospital. Significant improvements (p < 0.001) were found for FEV1 (+17%, 95% CI, 11 to 24), RV (-687 mL, 95% CI, -918 to -456), 6MWD (+61 m, 95% CI, 42 to 80), and SGRQ (-11 points, 95% CI, -17 to -6). Two patients died: 1 after 58 days due to progressive respiratory failure and 1 after 338 days of follow-up due to a myocardial infarction. Seventeen percent of the patients underwent valve replacement and 22% of the initially treated patients had permanent valve removal. In 22% of the patients, pneumothoraces occurred before 6 months, and none occurred between 6 and 12 months. CONCLUSIONS: EBV treatment results in clinically relevant benefits at 1 year of follow-up. Maintenance bronchoscopies to achieve this are needed. This study supports the use of EBV treatment in carefully selected patients with severe emphysema without collateral ventilation.
BACKGROUND: One-way endobronchial valve (EBV) treatment has shown safety and efficacy at 6 months after treatment in patients with severe emphysema and confirmed absence of interlobar collateral ventilation. Longer follow-up in this subgroup is not available. OBJECTIVES: To investigate the efficacy and safety of EBV treatment of the STELVIO cohort at a 1-year follow-up. METHODS:Emphysemapatients who have been treated with EBV in the STELVIO trial were invited for a voluntary 1-year follow-up visit. Both the original treatment group and the control group who crossed over to treatment have been included. Analyses are performed on the patients who attended the 1-year follow-up visit. RESULTS: Sixty-four patients received EBV treatment. At 1 year, 40 patients (26 female; mean age 59 ± 8 years; FEV1 0.86 ± 0.29 L; RV 4.56 ± 1.00 L; 6MWD 367 ± 78 m; and SGRQ 56 ± 13 points) visited the hospital. Significant improvements (p < 0.001) were found for FEV1 (+17%, 95% CI, 11 to 24), RV (-687 mL, 95% CI, -918 to -456), 6MWD (+61 m, 95% CI, 42 to 80), and SGRQ (-11 points, 95% CI, -17 to -6). Two patients died: 1 after 58 days due to progressive respiratory failure and 1 after 338 days of follow-up due to a myocardial infarction. Seventeen percent of the patients underwent valve replacement and 22% of the initially treated patients had permanent valve removal. In 22% of the patients, pneumothoraces occurred before 6 months, and none occurred between 6 and 12 months. CONCLUSIONS:EBV treatment results in clinically relevant benefits at 1 year of follow-up. Maintenance bronchoscopies to achieve this are needed. This study supports the use of EBV treatment in carefully selected patients with severe emphysema without collateral ventilation.
Authors: Jorine E Hartman; Nick H T Ten Hacken; Karin Klooster; H Marike Boezen; Mathieu H G de Greef; Dirk-Jan Slebos Journal: Eur Respir J Date: 2012-03-22 Impact factor: 16.671
Authors: Felix J F Herth; Marc Noppen; Arschang Valipour; Sylvie Leroy; Jean-Michel Vergnon; Joachim H Ficker; Jim J Egan; Stefano Gasparini; Carlos Agusti; Debby Holmes-Higgin; Armin Ernst Journal: Eur Respir J Date: 2012-01-26 Impact factor: 16.671
Authors: Federico Venuta; Marco Anile; Daniele Diso; Carolina Carillo; Tiziano De Giacomo; Antonio D'Andrilli; Francesco Fraioli; Erino A Rendina; Giorgio F Coloni Journal: Eur Respir J Date: 2011-10-17 Impact factor: 16.671
Authors: Matthew S Brown; Hyun J Kim; Fereidoun G Abtin; Charlie Strange; Maya Galperin-Aizenberg; Richard Pais; Irene G Da Costa; Arash Ordookhani; Daniel Chong; Chiayi Ni; Michael F McNitt-Gray; Donald P Tashkin; Jonathan G Goldin Journal: Eur Radiol Date: 2012-04-01 Impact factor: 5.315
Authors: Karin Klooster; Nick H T ten Hacken; Jorine E Hartman; Huib A M Kerstjens; Eva M van Rikxoort; Dirk-Jan Slebos Journal: N Engl J Med Date: 2015-12-10 Impact factor: 91.245
Authors: Arschang Valipour; Felix J F Herth; Otto C Burghuber; Gerard Criner; Jean-Michel Vergnon; Jonathan Goldin; Frank Sciurba; Armin Ernst Journal: Eur Respir J Date: 2013-07-11 Impact factor: 16.671
Authors: Geert M Verleden; Lieven Dupont; Jonas Yserbyt; Veronique Schaevers; Dirk Van Raemdonck; Arne Neyrinck; Robin Vos Journal: J Thorac Dis Date: 2017-09 Impact factor: 2.895
Authors: Felix J F Herth; Dirk-Jan Slebos; Pallav L Shah; Martin Hetzel; Gerald Schmid-Bindert; Adam S LaPrad; Gaëtan Deslée; Arschang Valipour Journal: Respiration Date: 2019-11-19 Impact factor: 3.580
Authors: Ralf Eberhardt; Dirk-Jan Slebos; Felix J F Herth; Kaid Darwiche; Manfred Wagner; Joachim H Ficker; Christoph Petermann; Ralf-Harto Hübner; Franz Stanzel; Narinder S Shargill; Arschang Valipour Journal: Respiration Date: 2021-07-23 Impact factor: 3.580